MVP.ASX: Appendix 4C and Quarterly Activity Report 31 March 2026

Appendix 4C and Quarterly Activity Report 31 March 2026

Stock	Medical Developments International Ltd (MVP.ASX)
Release Time	24 Apr 2026, 8:58 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Quarterly update and strong cash flow for MVP

Key Points

Positive free cashflow for Q3 and YTD
Penthrox revenue up $4.9 million
Penthrox volume growth of 26% in Australian hospitals

Full Summary

Medical Developments International Limited (ASX: MVP) has released its Appendix 4C and Quarterly Activity Report for the quarter ended 31 March 2026 (Q3 FY26). The company reported positive free cashflow for Q3 and YTD, with Penthrox revenue up $4.9 million year-to-date compared to the prior corresponding period. Penthrox volume growth was 26% in the Australian hospital segment, and European in-market demand for Penthrox was up 19% versus the prior corresponding period. The company is close to completing paediatric label approvals for Penthrox in Europe, which will broaden the addressable market. The Respiratory segment saw lower revenue due to softer demand in the US, though higher pricing in the US helped offset this. The company continues to focus on initiatives to accelerate Penthrox penetration in Australia and grow the product in Europe.

Guidance

In FY26, the Group expects to finalise approvals for the paediatric indication of Penthrox in Europe and support the new label launch. Seasonally softer demand conditions in the Respiratory segment are expected to result in earnings that are lower in the second half of FY26 compared to the first half.